In SCID/CB17 mice bearing EG20 patient-derived xenografts, daily oral gavage of Azelnidipine at 2 mg/kg for 42 days significantly reduced tumor weights compared with vehicle, with a reported reduction of 66.45%. In male Wistar rats receiving NA, oral Azelnidipine was studied against an NA group without vasodilator treatment. The rat study reported that treatments with azelnidipine and hydralazine lowered SBP and DBP, while these effects were partially insignificant. [2,3]
Azelnidipine treatment in patient-derived xenografts
Animal study · EG20; SCID/CB17 mice; patient-derived xenograft (PDX) [2]
SCID/CB17 mice bearing EG20 patient-derived xenografts received Azelnidipine at 2 mg/kg by daily oral gavage for 42 days. Tumor weights were significantly reduced compared with the vehicle group, with a reported reduction of 66.45%.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- 42 days; daily
- Azelnidipine 2 mg/kg
- Model: EG20; SCID/CB17 mice; patient-derived xenograft (PDX)
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Azelnidipine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Azelnidipine inhibits PDX tumor growth in vivo (S61, S62, S64); Materials and methods > PDX model (S133, S134)
tumor weights: tumor weights; comparator: vehicle group — Results > Azelnidipine inhibits PDX tumor growth in vivo (S64)
Azelnidipine 2 mg/kg · Results > Azelnidipine inhibits PDX tumor growth in vivo (S62, S64)
Azelnidipine treatment in NA-treated Wistar rats
Animal study · 8-week-old male Wistar rats; NA plus azelnidipine, 8 [3]
Male Wistar rats receiving NA were given Azelnidipine orally over 14 days, with an NA group without vasodilator treatment as the comparator. The study reported that treatments with azelnidipine and hydralazine lowered SBP and DBP, while these effects were partially insignificant.
Conditions shared by the study groups
- Route
- oral administration
- Treatment course
- over 14 days
- Azelnidipine 9.7 ± 0.3 mg/day
- Model: 8-week-old male Wistar rats; NA plus azelnidipine, 8
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Azelnidipine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Animals and chemicals (S1); Methods > BP monitoring and experiment protocol (S9, S10, S13, S14); Results (S26, S28, S33); Fig. 1 legend (S48, S49)
averages of SBP and DBP: averages of SBP and DBP; comparator: NA group without vasodilator treatment — Results (S26, S28)
Azelnidipine 9.7 ± 0.3 mg/day · Methods > BP monitoring and experiment protocol (S9); Results (S28, S33)